Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

This long-term follow-up confirmed the observed benefit of adding pertuzumab to adjuvant trastuzumab and chemotherapy on invasive disease–free survival (HR 0.76; 95% CI, 0.64 to 0.91); no survival benefit was seen but longer-term follow-up is required.

Source:

Journal of Clinical Oncology